06998.HK
Genor Biopharma Holdings Limited
HKSE · Healthcare · Biotechnology · CN
HKD 1.69
+2.42%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +278.3%
- EBIT
- +248.9%
- EPS
- +115.7%
- Free cash flow
- +152.5%
- Operating cash flow
- +158.8%
Forward estimates
Based on analyst estimates
- Revenue
- -99.7%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +426.1%
- EBITDA
- +3.3%
- EBIT
- -3.4%
- Net income
- +3.0%
- EPS
- -72.0%
- Free cash flow
- +427.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026